Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Independent of LDL Cholesterol and Statin Use: Results of the Leader Trial

Canadian Journal of Cardiology - Canada
doi 10.1016/j.cjca.2018.07.220

Related search